Stock Pick - MNKD
So you think Al made this deal with Sanofi after they hired a company to do all due diligence (Greenfield) on the transaction and did not ensure they would do what they need to survive. It take a year for Insurance companies at least to put new drugs on their tier 1 or 2 coverage. That happens next year. No commercials yet for drug, why they are waiting to do all this at once. They fired Hakan or relived him of his duties and he is still on payroll to 2017. Your not real bright if you think this is just Sanofi can't sell afrezza. They are not trying too yet.
So you think Al made this deal with Sanofi after they hired a company to do all due diligence (Greenfield) on the transaction and did not ensure they would do what they need to survive. It take a year for Insurance companies at least to put new drugs on their tier 1 or 2 coverage. That happens next year. No commercials yet for drug, why they are waiting to do all this at once. They fired Hakan or relived him of his duties and he is still on payroll to 2017. Your not real bright if you think this is just Sanofi can't sell afrezza. They are not trying too yet.
Louis,
Louis,
louis, good luck, i got my 600+ worth...im with you.
louis, good luck, i got my 600+ worth...im with you.
"MannKind's effort to raise more money to sell Afrezza on its own -- or find another partner willing to do so -- will also be complicated by fixed spending requirements. Most notably, the FDA is requiring MannKind to conduct a five-year, 8,000-patient lung safety study of Afrezza. This study, not yet started, was to be funded by Sanofi.
The company can tap an existing At-The-Money equity financing facility for additional cash and founder Al Mann can also lend the company $30 million. But without Sanofi's support, these funds are like putting a bandage on a bullet wound to the chest.
Game over, MannKind."
"MannKind's effort to raise more money to sell Afrezza on its own -- or find another partner willing to do so -- will also be complicated by fixed spending requirements. Most notably, the FDA is requiring MannKind to conduct a five-year, 8,000-patient lung safety study of Afrezza. This study, not yet started, was to be funded by Sanofi.
The company can tap an existing At-The-Money equity financing facility for additional cash and founder Al Mann can also lend the company $30 million. But without Sanofi's support, these funds are like putting a bandage on a bullet wound to the chest.
Game over, MannKind."
LOL bought 800 more at $3.69, just had to
Sorry WallstreetCappers, your just reading FUD.
It all doesn't matter in the end. Just watch.
LOL bought 800 more at $3.69, just had to
Sorry WallstreetCappers, your just reading FUD.
It all doesn't matter in the end. Just watch.
Most everything is getting beat up this week market in a slide. Poo I am holding AA also getting hurt today just stay put on that. Not sure what to do with MNKD they need as a company to come up with a plan find a new partner or something. It may be heading to BK who knows.
Most everything is getting beat up this week market in a slide. Poo I am holding AA also getting hurt today just stay put on that. Not sure what to do with MNKD they need as a company to come up with a plan find a new partner or something. It may be heading to BK who knows.
Hot Forum Topics
- 🤢🥴💩_ Fubah's risky baseball bets _🥶😲🥵 457,386
- Sunday 10/04/2026 686
- NFL LOCKED IN! 104,313
- ***Macwesties * Sun. Oct. 04, 2026 * Week #4 * NFL Football Plays*** 8,408
- This Seattle Line Is Begging for a Discussion 2,812
- NCAA FOOTBALL. 151 33,486
- Lions vs Panthers in game live SNF 1,843
- __________ 📌 🏈 ?? Fubah's NFL 2026: Week 04 🚩🚩🚩🚩 13,206
- Sunday nFl Wk 4 8,147
- NFL THREAD * 151 * 16,839
Warning - External Link
Report User
This post is spam
Delete Post
Remove Thread
Scan Results
Login/Register
Accounts are free and easy to create.
Search
